NasdaqGS - Nasdaq Real Time Price USD
ICON Public Limited Company (ICLR)
158.17 +15.50 (+10.86%)
At close: June 24 at 4:00:01 PM EDT
158.00 -0.17 (-0.11%)
Pre-Market: 7:01:19 AM EDT
Trade ICON on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for ICLR
- Previous Close
142.67 - Open
147.79 - Bid 116.46 x 200
- Ask 189.28 x 200
- Day's Range
147.71 - 161.92 - 52 Week Range
66.57 - 211.00 - Volume
2,406,383 - Avg. Volume
1,171,858 - Market Cap (intraday)
12.116B - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
69.68 - EPS (TTM)
2.27 - Earnings Date (est.) Jul 23, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
154.81
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ICLR
13.20%
S&P 500 (^GSPC)
7.49%
1-Year Return
ICLR
6.48%
S&P 500 (^GSPC)
20.78%
3-Year Return
ICLR
30.12%
S&P 500 (^GSPC)
69.22%
5-Year Return
ICLR
26.02%
S&P 500 (^GSPC)
72.47%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/24/2026
Market Cap
12.10B
Enterprise Value
14.84B
Trailing P/E
69.56
Forward P/E
15.08
PEG Ratio (5yr expected)
0.52
Price/Sales (ttm)
1.49
Price/Book (mrq)
1.30
Enterprise Value/Revenue
1.79
Enterprise Value/EBITDA
19.40
Financial Highlights
Profitability and Income Statement
Profit Margin
2.78%
Return on Assets (ttm)
3.85%
Return on Equity (ttm)
2.46%
Revenue (ttm)
8.25B
Net Income Avi to Common (ttm)
229.34M
Diluted EPS (ttm)
2.27
Balance Sheet and Cash Flow
Total Cash (mrq)
647.29M
Total Debt/Equity (mrq)
38.68%
Levered Free Cash Flow (ttm)
769.35M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
202.10
+8.31%
Mkt Cap 9.735B
Industry Diagnostics & Research
1,203.18
+4.02%
Mkt Cap 24.313B
Industry Diagnostics & Research
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreIcon Earnings: Strong Bookings Support Recovery, but Headwinds Hinder Near-Term Profitability
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon’s services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
RatingPrice TargetIcon Earnings: Accounting Overhang Lifted, Underlying Demand Trends Encouraging as Shares Soar 15%
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon’s services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
RatingPrice TargetIcon: Downgrading Moat Rating to None; Yet Shares Appear Undervalued Amid Significant Pullback
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon’s services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
RatingPrice TargetIcon: Downgrading Moat Rating to None; Yet Shares Appear Undervalued Amid Significant Pullback
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon’s services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
RatingPrice Target